Clinical trials: Acute Myelogenous Leukemia (AML)
Malignant Disease, Solid Tumor
A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies
This is a window-of-opportunity trial to determine if atorvastatin given for 1 to 4 weeks at a dose of 80 milligrams per day (mg/day) is sufficient to decrease the level of conformational mutant tumor protein 53 (p53) in…
- Conditions
- Malignant Disease, Solid Tumor, Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT03560882
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Joaquina Baranda
Acute Myeloid Leukaemia (AML), Leukemia
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
The purpose of this research study is to test the safety and efficacy of a new drug combination with three agents, azacitidine, venetoclax and tagraxofusp.
- Conditions
- Acute Myeloid Leukaemia (AML), Leukemia, Blood Cancer, Blood Cancers
- Trial name
- NCT07148180
- Testing
- Tagraxofusp, Azacitidine (AZA), Venetoclax
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Jacqueline Garcia, MD
Leukemia, Myeloid, Acute
Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML
This study will evaluate the investigational drug Midostaurin in various doses given with ATRA and CLAG chemotherapy. Midostaurin is a FLT3 inhibitor that is activated or overexpressed in a significant proportion of AML patients.
- Trial name
- CLAG ATRA AML (NCT01161550)
- Testing
- Granulocyte colony-stimulating factor (G-CSF), Cladribine, Cytarabine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Washington University School of Medicine
Hematologic Diseases, Hematologic Malignancy
CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies
This is a Phase II trial testing disease-specific myeloablative conditioning regimens for preparatory cytoreduction of patients receiving allogeneic HLA-compatible related or unrelated transplants of GCSF-mobilized peripheral…
- Conditions
- Hematologic Diseases, Hematologic Malignancy, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
- Trial name
- 2019-KOE-001 (NCT04282174)
- Testing
- CliniMACS, Bone Marrow Transplant, Hyperfractionated Total Body Irradiation
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Baptist Health South Florida
AML
Intermediate-dose HAD Regimen for CEBPA Double-mutated AML
AML is highly heterogeneous in pathogenesis, and CEBPA double-mutated (CEBPAdm) AML is a common type of leukemia in China. Currently, no targeted therapies for CEBPAdm, and chemotherapy and transplantation are still the treatment…
- Trial name
- HADCEBPA2023 (NCT06529250)
- Testing
- HAD, Daunorubicin+Cytarabine
- Where
- China
- Volunteers
- 148 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Myeloid Leukemia
A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia
This is an open label, multi-center, phase 1 study of DSP-2033 (Alvocidib) in combination with cytarabine/mitoxantrone (ACM regimen) or cytarabine/daunorubicin (A+7+3 regimen) in patients with acute myeloid leukemia (AML).
- Trial name
- AML (NCT03563560)
- Testing
- Alvocidib, Cytarabine, Mitoxantrone
- Where
- 11 sites in Japan
- Volunteers
- 10 people
- Sponsor
- Sumitomo Pharma Co., Ltd.
Acute Myeloid Leukemia
Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newly Diagnosed Acute Myeloid Leukemia
This single-armed study aims to investigate the safety and efficacy of sonrotoclax in combination with intensive chemotherapy in subjects with newly diagnosed AML.
- Trial name
- NCT06497062
- Testing
- sonrotoclax, idarubicin/daunorubicin, Cytarabine
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Safety, Antitumor Activity
FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid Neoplasms
This is a Phase 2, open-label, multicenter study to safety \& tolerability, antitumor activity, and pharmacokinetics of FCN-338 in Combination with szacitidine (AZA) or chemotherapy(erythromycin, cytarabine(Ara-C)) in Patients…
- Conditions
- Safety, Antitumor Activity, PK Profile
- Trial name
- NCT06858618
- Testing
- FCN-338 + Azacitidine, FCN-338 + erythromycin+ Ara-C
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS
Targeted immune therapy with gemtuzumab ozogamicin (Mylotarg) in combination with chemotherapy followed by allogeneic stem cell transplantation will be given to patients with high risk acute myelogenous leukemia (AML) or…
- Trial name
- NCT02221310
- Testing
- Gemtuzumab Ozogamicin
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- New York Medical College
Treatment-naive or Relapsed or Refractory Acute Myeloid Leukemia (AML)
A Study to Evaluate the Tolerance and Efficacy of Mitoxantrone Hydrochloride Liposome Injection Combined With Cytarabine in Patients With Acute Myeloid Leukemia (AML)
This is an open-label, multi-cohort, multi-center Phase Ib/II clinical study to evaluate the tolerance and efficacy of Mitoxantrone Hydrochloride liposome injection combined with cytarabine in patients with Acute Myeloid Leukemia…
- Trial name
- NCT05100303
- Testing
- Mitoxantrone Hydrochloride liposome injection, Cytarabine (LoDAC)
- Where
- China
- Volunteers
- 58 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Acute Myelogenous Leukemia AML, Myelodysplastic Syndrome MDS
Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDS
Phase II trial combining azacitidine with valproic acid as maintenance therapy post allogeneic stem cell transplantation in patients with high-risk MDS/AML.
- Trial name
- NCT02124174
- Testing
- Vidaza and Valproic Acid
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Patrick Stiff
Recurrent Adult Acute Myeloid Leukemia
Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
This phase I trial studies the side effects and best dose of ibrutinib when given together with idarubicin and cytarabine in treating patients with acute myeloid leukemia that has returned after a period of improvement or has not…
- Trial name
- NCT02635074
- Testing
- Cytarabine, Ibrutinib, Idarubicin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Steven E. Coutre
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
SCT Plus Immune Therapy in Average Risk AML/MDS
Allogeneic stem cell transplantation followed by targeted immune therapy with Gemtuzumab Ozogamicin (Mylotarg) will be given to patients with average risk AML or MDS.
- Trial name
- NCT02117297
- Testing
- Gemtuzumab Ozogamicin
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- New York Medical College
Acute Myeloid Leukaemia (AML), Follicular Lymphoma ( FL)
A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
The TEMPUS AQUARIUS Study is a non-interventional, longitudinal observational study focused on hematological malignancies. It will collect rich molecular (multi-omic) and clinical data from patient cohorts through serial blood…
- Trial name
- Aquarius (NCT07154823)
- Testing
- None - Observational Study
- Where
- 13 sites in United States
- Volunteers
- 550 people
- Sponsor
- Tempus AI
Acute Biphenotypic Leukemia, Acute Leukemia
Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome
This phase II trial tests how well removing CD45RA positive naive T cells works to prevent graft versus host disease in older patients undergoing standard of care allogeneic hematopoietic stem cell transplantation for the…
- Conditions
- Acute Biphenotypic Leukemia, Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia
- Trial name
- NCT07819396
- Testing
- Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Myeloid Leukemia
Autologous Bone Marrow Transplant for Children With Acute Myelogenous Leukemia (AML) in First Complete Remission
This study proposes to transfer marker genes (detectable genetic traits or segments of DNA that can be identified and tracked) into aliquots of marrow obtained for Bone Marrow Transplant (BTM) in patients in remission of Acute…
- Trial name
- NCT00667927
- Testing
- Busulfan, Cyclophosphamide, Mesna
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- St. Jude Children's Research Hospital
Acute Myeloid Leukemia
Microtransplantation in Older Patients With Acute Myeloid Leukemia
The purpose of this study is to see whether HLA-mismatched donor cells infusion with chemotherapy (microtransplantation，MST) could increase complete remission (CR) and improve survival in older patients with acute myeloid…
- Trial name
- NCT02831192
- Testing
- microtransplantation
- Where
- China
- Volunteers
- 150 people
- Sponsor
- The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Leukemia, Myeloid, Acute
A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML)
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-486 (ONUREG®) in combination with venetoclax in relapsed and/or refractory Acute Myeloid Leukemia (AML) and newly diagnosed AML.
- Trial name
- OMNIVERSE (NCT04887857)
- Testing
- CC-486, Venetoclax
- Where
- 10 sites in United States, Australia
- Volunteers
- 6 people
- Sponsor
- Celgene
AML in Remission
Comparing the Consolidation Regimens of IDA With Intermediate-dose Cytarabine Versus Intermediate-dose Cytarabine Alone for Elderly AML Patients
This study evaluates Idarubicin (IDA) in combination with the intermediate-dose cytarabine, compared with intermediate-dose cytarabine alone, as a consolidation treatment for elderly AML in first remission.
- Trial name
- NCT04216771
- Testing
- Idarubicin, ID cytarabine
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Fujian Medical University
Congenital Amegakaryocytic Thrombocytopenia, Diamond-blackfan Anemia
Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders
RATIONALE: Monoclonal antibodies, such as alemtuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Conditions
- Congenital Amegakaryocytic Thrombocytopenia, Diamond-blackfan Anemia, Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00301834
- Testing
- alemtuzumab, busulfan, cyclosporine
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- University of California, San Francisco
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.